Taligen Therapeutics
Cambridge, Massachusetts, United States
About Taligen Therapeutics
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $78.8M
- Funding stage: M&A
- Last round: Series B (Aug 2010)
- Website: taligentherapeutics.com
- Phone: +1 617-444-8443
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/taligen-therapeutics-2554160 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.